Trial Profile

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Cisplatin (Primary) ; Domvanalimab (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Zimberelimab (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms TROPHY U-01
Sponsors Gilead Sciences; Immunomedics

Most Recent Events

04 Sep 2024 Planned number of patients changed from 643 to 827.
04 Sep 2024 Planned End Date changed from 1 Jul 2026 to 1 Jun 2030.
04 Sep 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jun 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com